Abstract: Fluid and positron emission tomography (PET) biomarkers that enable the detection of the hallmark proteins of Alzheimer’s disease (AD) (amyloid and tau) have revolutionized our approach to the diagnosis of AD. The evolution of AD diagnostic criteria to include biological characterization (Alzheimer’s Association Working Group, 2023) provides an appropriate framework to reduce levels of clinico-pathologic mismatch and improve in-vivo diagnostic accuracy. As the therapeutic landscape for neurodegenerative disease evolves, it is increasingly incumbent on clinicians to provide timely, and pathologically precise diagnoses for patients. However, the expensive and invasive nature of these tests limits their scalability.